Related Experiment Video
Updated: Aug 10, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis
V Byrnes1, N Afdhal, T Challies
1Department of Gastroenterology, Beth Israel Deaconess Hospital, Harvard Medical School, Boston, MA, USA. vbyrnes@bidmc.harvard.edu
Abstract:
Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity. Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta. We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Multiple Sclerosis l: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
